Resources from the same session
341MO - Impact of aging on the genetic and transcriptional landscape of advanced breast cancer: an AURORA program (BIG 14-01) subanalysis
Presenter: Gabriele Zoppoli
Session: Mini oral session 1: Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
342MO - Metastatic hormone receptor-positive breast cancer outcomes in 628 patients with BRCA1, BRCA2, or PALB2 pathogenic variants: Real-world data analysis of genomics and targeted therapy sequencing
Presenter: Gerneiva Parkinson
Session: Mini oral session 1: Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
LBA21 - Human epidermal growth factor receptor 2 (HER2)-low and HER2-ultralow status determination in tumors of patients (pts) with hormone receptor–positive (HR+) metastatic breast cancer (mBC) in DESTINY-Breast06 (DB-06)
Presenter: Giuseppe Viale
Session: Mini oral session 1: Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
343MO - Unraveling the mechanisms of action and resistance to trastuzumab deruxtecan (T-DXd): Supplementary biomarker analyses from DAISY trial
Presenter: Maria Fernanda Mosele
Session: Mini oral session 1: Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
Invited Discussant 341MO, 342MO, LBA21 and 343MO
Presenter: Christos Sotiriou
Session: Mini oral session 1: Breast cancer, metastatic
Resources:
Slides
Webcast
344MO - ESG401, a novel Trop2 antibody-drug conjugate (ADC), and its efficacy evidence in HER2-negative metastatic breast cancer with brain metastases
Presenter: Fei Ma
Session: Mini oral session 1: Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
LBA22 - Effects of trastuzumab deruxtecan (T-DXd) vs choice of chemotherapy (TPC) on patient-reported outcomes (PROs) in hormone receptor-positive, HER2-low or HER2-ultralow metastatic breast cancer (mBC): Results from DESTINY-Breast06
Presenter: Xichun Hu
Session: Mini oral session 1: Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
345MO - IBI354 (anti-HER2 antibody-drug conjugate [ADC]) in patients (pts) with advanced solid tumors and breast cancer (BC): Results from a phase I study
Presenter: Christina Teng
Session: Mini oral session 1: Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
346MO - Trastuzumab deruxctecan (T-DXd) associated interstitial lung disease (ILD) in a large real-world French cohort of patients with HER2-driven breast cancer and other malignancies
Presenter: Lana Elu
Session: Mini oral session 1: Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast